Relaxing effects induced by the soluble guanylyl cyclase stimulator BAY 41-2272 in human and rabbit corpus cavernosum

被引:43
|
作者
Baracat, JS [1 ]
Teixeira, CE [1 ]
Okuyama, CE [1 ]
Priviero, FBM [1 ]
Faro, R [1 ]
Antunes, E [1 ]
De Nucci, G [1 ]
机构
[1] Univ Estadual Campinas, Fac Med Sci, Dept Pharmacol, BR-13081970 Campinas, SP, Brazil
关键词
corpus cavernosum; BAY; 41-2272; soluble guanylyl cyclase; sildenafil; nitric oxide (NO);
D O I
10.1016/j.ejphar.2003.08.012
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
5-Cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-pyrimidin-4-ylamine (BAY 41-2272) is a potent soluble guanylyl cyclase stimulator in a nitric oxide (NO)-independent manner. The relaxant effect of BAY 41-2272 was investigated in rabbit and human corpus cavernosum in vitro. BAY 41-2272 (0.01 - 10 muM) relaxed both rabbit (pEC(50) = 6.82 +/- 0.06) and human (pEC(50) = 6.12 +/- 0.10) precontracted cavemosal strips. The guanylyl cyclase inhibitor (ODQ, 10 muM) caused significant rightward shifts in the concentration-response curves for BAY 41-2272 in rabbit (4.7-fold) and human (2.3-fold) tissues. The NO synthesis inhibitor (N-nitro-(L)-arginine methyl ester ((L)-NAME), 100 muM) also produced similar rightward shifts, revealing that BAY 41-2272 acts synergistically with endogenous NO to elicit its relaxant effect. The results also indicate that ODQ is selective for the NO-stimulated enzyme, since relaxations evoked by BAY 4 1 2272 were only partly attenuated by ODQ. The present study shows that both BAY 41-2272 and sildenafil evoke relaxations independent of inhibition of haem in soluble guanylate cyclase. Moreover, there is no synergistic effect of the two compounds in corpus cavernosum. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:163 / 169
页数:7
相关论文
共 50 条
  • [41] Increased cyclic guanosine monophosphate synthesis and calcium entry blockade account for the relaxant activity of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in the rabbit penile urethra
    Toque, Haroldo A. Flores
    Antunes, Edson
    Teixeira, Cleber E.
    De Nucci, Gilberto
    UROLOGY, 2008, 72 (03) : 711 - 715
  • [42] Anti-remodeling potencies of the soluble guanylate cyclase activator BAY 41-2272 in human lung fibroblasts
    Lambers, Christopher
    Roth, Michael
    Hofbauer, Elisabeth
    Petkov, Venzel
    Block, Lutz-Henning
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [43] Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272
    Mullershausen, F
    Russwurm, M
    Friebe, A
    Koesling, D
    CIRCULATION, 2004, 109 (14) : 1711 - 1713
  • [44] Cardiorenal actions of the novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure in comparison to nitroglycerin
    Boerrigter, G
    Costello-Boerrigter, LC
    Lapp, H
    Cataliotti, A
    Tsuruda, T
    Harty, GJ
    Stasch, JP
    Burnett, JC
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (06) : 253A - 254A
  • [45] Mechanisms underlying relaxation of rabbit aorta by BAY 41-2272, a nitric oxide-independent soluble guanylate cyclase activator
    Priviero, FBM
    Baracat, JS
    Teixeira, CE
    Claudino, MA
    De Nucci, G
    Antunes, E
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2005, 32 (09) : 728 - 734
  • [46] The effects of the sGC stimulator BAY 41-2272 in an experimental model of Duchenne Muscular Dystrophy (DMD)
    Krishnan, Shalini Murali
    Hagelschuer, Ina
    Mathar, Ilka
    Meyer, Jutta
    Hartmann, Elke
    Pavkovic, Mira
    Sandner, Peter
    JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17 (01)
  • [47] Effects Of Soluble Guanylate Cyclase Activator BAY 41-2272 In Murine Models Of Pulmonary Hypertension And Acute Lung Injury
    Voelker, M. T.
    Hoelman, A.
    Fichtner, F.
    Sack, U.
    Kamprad, M.
    Busch, T.
    Kaisers, U.
    Laudi, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181
  • [48] Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease
    Boerrigter, Guido
    Burnett, John C., Jr.
    CARDIOVASCULAR DRUG REVIEWS, 2007, 25 (01): : 30 - 45
  • [49] Antiplatelet properties of a novel, non-NO-based soluble guanylate cyclase activator, BAY 41-2272
    Hobbs, AJ
    Moncada, S
    VASCULAR PHARMACOLOGY, 2003, 40 (03) : 149 - 154
  • [50] Inhibitory effects on human eosinophil chemotaxis in vitro by BAY 41-2272, an activator of nitric oxide-independent site of soluble guanylate cyclase
    Thomazzi, SM
    Moreira, J
    De Nucci, G
    Antunes, E
    BIOCHEMICAL PHARMACOLOGY, 2005, 69 (06) : 875 - 882